ABBOTT PARK, Ill., June 25, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data on a number of its life-changing products to treat people with structural heart diseases. The data included findings on the MitraClip™ system for transcatheter mitral valve repair and data on two first-in-the-world devices approved in the EU: the TriClip™ system* for transcatheter tricuspid valve repair and the Tendyne™ transcatheter mitral valve implantation system* for people needing a replacement mitral valve.
Clinical and real-world evidence show that transcatheter devices can dramatically change the treatment approaches for complex cardiac conditions. The body of data spanning these technologies show continued positive outcomes for less invasive transcatheter therapies and emphasize Abbott's commitment to advancing new treatment options for people with mitral regurgitation (MR) and tricuspid regurgitation (TR).
The new late-breaking data on Abbott's transcatheter structural heart therapies will be presented as part of a virtual three-day PCR e-Course held by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), June 25-27.
Treating Mitral Regurgitation with Repair and Replacement
One of the most common types of heart valve diseases, MR affects nearly one in 10 people over the age of 75, and is a condition in which the flaps, or leaflets, of the mitral valve do not close properly, allowing blood to flow backward into the heart. The disease can cause debilitating and sometimes fatal symptoms, yet people with MR are often not eligible for the standard-of-care open-heart surgery because of their age, frailty, comorbidities or other complicating factors. New data presented at the PCR e-Course demonstrate:
"Historically, people who were ineligible for standard-of-care surgeries to treat their mitral or tricuspid regurgitation were limited to symptom management, which does not address the underlying condition," said Paul Sorajja, M.D., the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital. "These devices treat extremely complex valve diseases that are debilitating and progress to very serious conditions when left untreated. The late-breaking data show significant and consistent reduction in regurgitation, allowing the heart valve to function as it is intended."
Driving New Treatment Options for Tricuspid Regurgitation with TriClip
Tricuspid valve regurgitation occurs when the valve between the two right chambers (right ventricle and right atrium) of the heart don't close, allowing blood to flow backwards into the right atrium of the heart. For people with TR, surgery has traditionally been the only treatment option available but is rarely performed due to its complexity and risks.
Building on the proven success of MitraClip's clip-based technology to combat regurgitation, data from the TRILUMINATE CE Mark study evaluating TriClip, the first minimally invasive, clip-based tricuspid valve repair device approved in the EU, shows the impact of the therapy for patients suffering from TR in 85 patients across 21 sites in Europe and the United States.
New late-breaking trial data with longer term follow-up (one-year) showed:
New Data for Patients with Severe Aortic Stenosis and Atrial Fibrillation
Additional U.S. IDE data from Abbott's structural heart portfolio were also presented during the PCR e-Course, including findings on two of its devices* commercially available in the EU: Amplatzer™ Amulet Left Atrial Appendage (LAA) Occluder* – a stroke prevention product for people with atrial fibrillation – and Portico™ transcatheter aortic valve replacement (TAVR).
These positive findings on Amplatzer and Portico presented as late-breaking clinical trials during the PCR e-Course add to the mitral and tricuspid late-breaking data and demonstrate the breadth of Abbott's structural heart portfolio.
"At Abbott, we are advancing science and innovative technology to ensure people living with structural heart diseases have safe and effective treatment options," said Michael Dale, senior vice president of Abbott's structural heart business. "The data presented during this year's PCR underscore our unwavering commitment to solve the health challenges of those managing debilitating heart conditions."
For U.S. important safety information on MitraClip, visit: https://www.structuralheartsolutions.com/us/mitraclip-isi.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.
*These products are available commercially in the EU and are in clinical trials in the United States.
The TriClip Transcatheter Tricuspid Valve Repair System is an investigational device only in the U.S.
The Tendyne Transcatheter Mitral Valve Implantation System is an investigational device only in the U.S.
The Amplatzer Amulet LAA Occluder is an investigational device only in the U.S.
The Portico Transcatheter Aortic Valve Replacement System is an investigational device only in the U.S.
The FlexNav Delivery system for Portico is an investigational device only in the U.S.